Adjuvant immunotherapies as a novel approach to bacterial infections.

abstract：:Monoclonal antibodies remain a primary product option for novel cancer treatment. The properties of an antibody are a function of the antigen specificity and constant region incorporated. The rapid advance in molecular understanding of cancer biology and the host-tumor interaction has defined a new range of targets fo...

journal_title：Immunotherapy

authors： Nicodemus CF

更新日期：2015-01-01 00:00:00

abstract：:Achieving long-term control of colorectal cancers with therapeutic vaccines that generate potent anti-tumor T cell and antibody responses has been a goal for more than two decades. To date, clinical trials of these vaccines have demonstrated induction of immune responses, but clinical benefit has been limited. Improve...

journal_title：Immunotherapy

authors： Patel SP,Osada T,Lyerly HK,Morse MA

更新日期：2014-01-01 00:00:00

abstract：:Therapeutic vaccination with dendritic cells (DCs) is recognized as an important experimental therapy for the treatment of minimal residual disease in acute myeloid leukemia. Many sources of leukemia-associated antigens and different methods for antigen loading of DCs have been used in an attempt to optimize anti-tumo...

journal_title：Immunotherapy

authors： van den Ancker W,van Luijn MM,Westers TM,Bontkes HJ,Ruben JM,de Gruijl TD,Ossenkoppele GJ,van de Loosdrecht AA

更新日期：2010-01-01 00:00:00

abstract：:Background: The purpose of this study was to assess the effectiveness of immune checkpoint inhibitors (ICIs) in advanced urothelial carcinoma. Materials & methods: We selected seven cohorts of patients published in four clinical trials. The restricted mean survival time (RMST) was used to analyze survival curves, perf...

journal_title：Immunotherapy

authors： Rivano M,Cancanelli L,Spazio LD,Chiumente M,Mengato D,Messori A

更新日期：2021-02-01 00:00:00

abstract：:The insight gained recently on the differentiation of naive CD4 T cells challenges the dogma that expression of canonical transcription factors and production of signature cytokines portray a commitment to a specific lineage and a point of no return. For almost two decades now, the belief has been that naive CD4 T cel...

journal_title：Immunotherapy

authors： Tartar DM,van Morlan AM,Zaghouani H

更新日期：2009-01-01 00:00:00

abstract：:Aim: To analyze the efficacy of checkpoint inhibitors in soft tissue sarcoma. Materials & methods: We retrospectively reviewed patients with advanced soft tissue sarcoma treated with ipilimumab and nivolumab. All patients who received at least one cycle were included. Results: One patient had a complete response and f...

journal_title：Immunotherapy

authors： Zhou M,Bui N,Bolleddu S,Lohman M,Becker HC,Ganjoo K

更新日期：2020-12-01 00:00:00

abstract：:Developing effective vaccines against Neisseria meningitidis serogroup B has been challenging for several reasons, including the fact that the capsular polysaccharide of N. meningitidis serogroup B is a poor antigen. Therefore, studies have focused on developing vaccines that target capsular protein meningococcal anti...

journal_title：Immunotherapy

authors： Esposito S,Castellazzi L,Bosco A,Musio A,Stoddard J

更新日期：2014-01-01 00:00:00

abstract：:Following cancer treatment, patients often report behavioral and cognitive changes. Novel cancer immunotherapeutics have the potential to produce sustained cancer survivorship, meaning patients will live longer with the side effects of treatment. Given the role of inflammatory pathways in mediating behavioral and cogn...

journal_title：Immunotherapy

authors： McGinnis GJ,Raber J

更新日期：2017-09-01 00:00:00

abstract：:Mycobacterium tuberculosis was one of the first human pathogens to be identified as the cause of a specific disease--TB. TB was also one of the first specific diseases for which immunotherapy was attempted. In more than a century since, multiple different immunotherapies have been attempted, alongside vaccination and ...

journal_title：Immunotherapy

authors： Doherty TM

更新日期：2012-06-01 00:00:00

abstract：:Rituximab is a chimeric monoclonal antibody used to treat hematologic and autoimmune diseases by depleting CD20-expressing B cells. Patients may develop hypogammaglobulinemia following treatment, with some demonstrating failure of B-cell recovery. The true frequency of hypogammaglobulinemia and/or impaired B-cell reco...

journal_title：Immunotherapy

authors： Sacco KA,Abraham RS

更新日期：2018-06-01 00:00:00

abstract：:Immunotherapy strategies for cancer are focused on inducing effective and specific cytotoxic responses mediated by CD8 T cells. On the other hand, immunosuppressive mechanisms induced by the tumor, such as the generation of tumor-specific CD4(+)CD25(+)FoxP3(+) Tregs, conspire against the efficacy of immunotherapies. I...

journal_title：Immunotherapy

authors： Muccioli M,Longstaff C,Benencia F

更新日期：2012-05-01 00:00:00

abstract：:The era of active immunotherapy has now been successfully ushered into the clinical realm of advanced prostate cancer. The successful clinical trial development and US FDA approval of sipuleucel-T (Provenge®) has revamped the therapeutic paradigm for advanced prostate cancer. Nonetheless, physician and patient educati...

journal_title：Immunotherapy

authors： Shore ND

更新日期：2011-08-01 00:00:00

abstract：:Evaluation of: Bostrom J, Shang-Fan Y, Kan D et al.: Variants of the antibody Herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323, 1610-1614 (2009). The longstanding held notion that one antibody equals one antigen and, hence, one function has been challenged in recent years. Improved t...

journal_title：Immunotherapy

authors： Valladares IG,Espinoza LR

更新日期：2009-09-01 00:00:00

abstract：:Evaluation of: Pesce B, Soto L, Sabugo F et al. Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients. Clin. Exp. Immunol. 171, 237-242 (2012). Clinical trials of a humanized anti-IL-6 receptor antibody, tocilizumab (TCZ), proved...

journal_title：Immunotherapy

authors： Tanaka T

更新日期：2013-07-01 00:00:00

abstract：:Aim: Previously, we constructed a novel anti-p21Ras single-chain antibody fragment, KGH-R1-single-chain fragment variant (ScFv). However, the immunoreactivity of this antibody toward p21Ras is still unclear. Materials & methods: ELISAs, immunohistochemistry, western blotting and immunofluorescence were used to identif...

journal_title：Immunotherapy

authors： Wang P,Pan X,Feng Q,Zou H,Cui J,He Y,Luo Y,Yang J

更新日期：2020-08-01 00:00:00

abstract：AIM:To assess carnitine serum levels and possible risk factors of its deficiency in patients with TB. PATIENTS & METHODS:All newly diagnosed TB patients admitted to an infectious diseases ward were recruited. Demographic, clinical and paraclinical characteristics of the patients were collected. Total carnitine serum c...

journal_title：Immunotherapy

authors： Hatamkhani S,Khalili H,Karimzadeh I,Abdollahi A,Jafari S,Khazaeipour Z

更新日期：2013-09-01 00:00:00

abstract：AIM:There is still no specific therapy for infection with the highly pathogenic avian influenza A virus (HPAI) H5N1, which caused 39 human cases with a 64% fatality rate in 2013. MATERIALS & METHODS:We prepared highly purified specific equine polyclonal immunoglobulin fragments (F(ab')2) against H5N1 and tested them f...

journal_title：Immunotherapy

authors： Herbreteau CH,Jacquot F,Rith S,Vacher L,Nguyen L,Carbonnelle C,Lotteau V,Jolivet M,Raoul H,Buchy P,Saluzzo JF

更新日期：2014-01-01 00:00:00

abstract：:There has been growing evidence that heat-shock protein (HSP) functions as an endogenous immunomodulator for innate and adaptive immune responses. Since HSPs inherently act as chaperones within cells, passive release (e.g., by cell necrosis) and active release (including release by secretion in the form of an exosome)...

journal_title：Immunotherapy

authors： Tamura Y,Torigoe T,Kukita K,Saito K,Okuya K,Kutomi G,Hirata K,Sato N

更新日期：2012-08-01 00:00:00

abstract：:Since the discovery of the CD40-CD154 costimulatory pathway and its critical role in the adaptive immune response, there has been considerable interest in therapeutically targeting this interaction with monoclonal antibodies in transplantation. Unfortunately, initial promise in animal models gave way to disappointment...

journal_title：Immunotherapy

authors： Pinelli DF,Ford ML

更新日期：2015-01-01 00:00:00

abstract：:Evaluation of: Fotin-Mleczek M, Duchardt KM, Lorenz C et al.: Messenger RNA-based vaccines with dual activity induce balanced TLR7-dependent adaptive immune responses and provide antitumor activity. J. Immunother. 34(1), 1-15 (2011). Two decades ago, mRNA was proposed as an active pharmaceutical ingredient for the the...

journal_title：Immunotherapy

authors： Van Lint S,Thielemans K,Breckpot K

更新日期：2011-05-01 00:00:00

abstract：AIM:This meta-analysis aims at assessing the correlation of PD-L1 levels and response PD-1/PD-L1 inhibitors in advanced malignant melanoma. METHODS:Eligible studies included those evaluating PD-1/PD-L1 inhibitors in advanced melanoma and correlating the outcomes to PD-L1 levels. RESULTS:After preclusion of ineligible...

journal_title：Immunotherapy

authors： Abdel-Rahman O

更新日期：2016-09-01 00:00:00

abstract：:In recent years, nanoparticulate-mediated drug delivery research has examined a full spectrum of nanoparticles that can be used in diagnostic and therapeutic cancer applications. A key aspect of this technology is in the potential to specifically target the nanoparticles to diseased cells using a range of molecules, i...

journal_title：Immunotherapy

authors： Fay F,Scott CJ

更新日期：2011-03-01 00:00:00

abstract：:Background: CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has emerged as a powerful immunotherapy in relapsed or refractory B-cell acute lymphoblastic leukemia. The changes in extramedullary (EM) disease in pediatric relapsed or refractory B-cell acute lymphoblastic leukemia after CAR T-cell therapy hav...

journal_title：Immunotherapy

authors： Huang J,Rong L,Wang E,Fang Y

更新日期：2021-01-01 00:00:00

abstract：:TB is an infectious disease that still has an enormous impact on public health worldwide. With the continuous increasing epidemic of multidrug-resistant TB, new drugs and vaccines are urgently needed. In the last decade there has been a broad advance in the knowledge of innate immunity in TB. Together with the growing...

journal_title：Immunotherapy

authors： Rivas-Santiago CE,Hernández-Pando R,Rivas-Santiago B

更新日期：2013-10-01 00:00:00

abstract：:Hematopoietic stem cell transplantation is the treatment of choice for many hematologic malignancies and genetic diseases. However, viral infections continue to account for substantial post-transplant morbidity and mortality. While antiviral drugs are available against some viruses, they are associated with significan...

journal_title：Immunotherapy

authors： Tzannou I,Leen AM

更新日期：2015-01-01 00:00:00

abstract：:Brain tumors present unique therapeutic challenges and they include glioblastoma (GBM) and metastases from cancers of other organs. Current treatment options are limited and include surgical resection, radiation therapy, laser interstitial thermal therapy and chemotherapy. Although much research has been done on the d...

journal_title：Immunotherapy

authors： Liu Y,Chongsathidkiet P,Crawford BM,Odion R,Dechant CA,Kemeny HR,Cui X,Maccarini PF,Lascola CD,Fecci PE,Vo-Dinh T

更新日期：2019-10-01 00:00:00

abstract：:Alemtuzumab (Campath®, Genzyme Corporation, MA, USA) is a potent monoclonal antilymphocyte, anti-CD52 antibody. Since the 1980s, alemtuzumab has been used extensively in organ transplantation as an induction agent - also with the aim of avoiding or reducing maintenance immunosuppression. We herein review the literatur...

journal_title：Immunotherapy

authors： Weissenbacher A,Boesmueller C,Brandacher G,Oellinger R,Pratschke J,Schneeberger S

更新日期：2010-11-01 00:00:00

abstract：:Programmed cell death-1 protein (PD-1) is an immune checkpoint that has gained popularity in the treatment of several advanced cancers. Inhibiting this checkpoint is known to enhance immune response, but is also known to diminish immune tolerance and to increase autoimmune toxicity. We discuss a case of rapid onset fu...

journal_title：Immunotherapy

authors： Araújo M,Ligeiro D,Costa L,Marques F,Trindade H,Correia JM,Fonseca C

更新日期：2017-06-01 00:00:00

abstract：AIM:Few studies have compared cluster immunotherapy and conventional administration regimens. The aim of this study was to establish the safety profile of these different regimens in patients with allergic respiratory diseases who received index-of-reactivity (IR)-standardized allergen extracts by the subcutaneous rout...

journal_title：Immunotherapy

authors： Quiralte J,Justicia JL,Cardona V,Dávila I,Moreno E,Ruiz B,García MA

更新日期：2013-12-01 00:00:00

abstract：:Aim: To investigate whether and how CD4+ T cells contribute to ILC2 activation during respiratory syncytial virus (RSV) infection. Methods: The methods of flow cytometry, quantitative PCR and ELISA were used in the present study. Results: Depletion of CD4+ T cells diminished the numbers of lung ILC2s as well as their ...

journal_title：Immunotherapy

authors： Han X,Bai S,Cui Y,Zhu W,Zhao N,Liu B

更新日期：2019-10-01 00:00:00